This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Exosomes Europe
5-6 June 2024
DoubleTree Tower of London

Lior Shaltiel
CEO at NurExone Biologic


Dr Lior Shaltiel is an awarded executive and scientist with extensive multidisciplinary international experience, specializing in drug delivery systems. Lior is the CEO and Director at NurExone Biologic Inc., an Israeli owned biopharmaceutical company deploying cutting-edge exosome technologies to treat Spinal Cord Injury/CNS indications through an intranasal administration.

In 2015, Lior initiated and serves Academic Head of the BioMed-MBA program at the Hebrew University Business School (HUBS) to align academic knowledge with entrepreneurial success. Lior has extensive industry experience to capitalize upon investment opportunities and most recently was appointed as the Chairman of the MedTech division at the Israeli Association of Engineers.

Agenda Sessions

  • Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach